Damoctocog alfa pegol - Bayer HealthCare Pharmaceuticals

Drug Profile

Damoctocog alfa pegol - Bayer HealthCare Pharmaceuticals

Alternative Names: BAY-949027; Damoctocog alfa pegol; peg rFVIII; PEG rFVIII mutein; PEGylated B-Domain-Delted Recombinant rFVIII; PEGylated BDD-rFVIII; rFVIII glycopegylated

Latest Information Update: 13 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bayer HealthCare Pharmaceuticals
  • Class Antihaemorrhagics; Blood coagulation factors; Polyethylene glycols; Recombinant proteins
  • Mechanism of Action Blood coagulation factor replacements; Factor X stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Haemophilia A
  • Phase II Haemorrhage

Most Recent Events

  • 30 Nov 2017 Phase-I clinical trials in Haemophilia A in Bulgaria (IV) (NCT03364998)
  • 30 Oct 2017 US FDA accepts BLA for damoctocog alfa pegol for Haemophilia A (Treatment-experienced) for review
  • 01 Sep 2017 Chemical structure information added
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top